Search
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Fulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalIt is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Sodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedSodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of ...
Mixtures: OLICLINOMEL N4-550 E EMULSION FOR INFUSION, OLICLINOMEL N7-1000 E EMULSION FOR INFUSIONErtapenem
go.drugbank.com/drugs/DB00303ApprovedInvestigational[L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnNicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.
Synonyms: N-(2-Hydroxyethyl)nicotinamide nitrate, N-(2-Hydroxyethyl)nicotinamide nitrate (ester)Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalRotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012...
Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalIt has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.